0 XP   0   0   0

Genovis AB (publ.)










Financial Health of Genovis




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Genovis AB (publ.)
Buy, Hold or Sell?

Should you buy, hold or sell Genovis?

I guess you are interested in Genovis AB (publ.). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Genovis

Let's start. I'm going to help you getting a better view of Genovis AB (publ.). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Genovis AB (publ.) even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Genovis AB (publ.) is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Genovis AB (publ.). The closing price on 2022-12-02 was kr42.45 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Genovis AB (publ.) Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very efficient.
The company is efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Genovis AB (publ.).

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Genovis earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compare Genovis to the Biotechnology industry mean.
  • A Net Profit Margin of 21.2% means that kr0.21 for each kr1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Genovis AB (publ.):

  • The MRQ is 21.2%. The company is making a huge profit. +2
  • The TTM is 29.6%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ21.2%TTM29.6%-8.4%
TTM29.6%YOY15.0%+14.5%
TTM29.6%5Y8.1%+21.5%
5Y8.1%10Y-293.6%+301.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ21.2%-223.6%+244.8%
TTM29.6%-281.7%+311.3%
YOY15.0%-344.8%+359.8%
5Y8.1%-450.1%+458.2%
10Y-293.6%-541.0%+247.4%
1.1.2. Return on Assets

Shows how efficient Genovis is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Genovis to the Biotechnology industry mean.
  • 3.6% Return on Assets means that Genovis generated kr0.04 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Genovis AB (publ.):

  • The MRQ is 3.6%. Using its assets, the company is less efficient in making profit.
  • The TTM is 7.0%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ3.6%TTM7.0%-3.4%
TTM7.0%YOY2.7%+4.4%
TTM7.0%5Y2.3%+4.7%
5Y2.3%10Y-8.9%+11.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.6%-9.9%+13.5%
TTM7.0%-8.9%+15.9%
YOY2.7%-9.3%+12.0%
5Y2.3%-11.7%+14.0%
10Y-8.9%-12.7%+3.8%
1.1.3. Return on Equity

Shows how efficient Genovis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Genovis to the Biotechnology industry mean.
  • 4.3% Return on Equity means Genovis generated kr0.04 for each kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Genovis AB (publ.):

  • The MRQ is 4.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 8.5%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ4.3%TTM8.5%-4.2%
TTM8.5%YOY3.2%+5.3%
TTM8.5%5Y2.8%+5.7%
5Y2.8%10Y-13.6%+16.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3%-12.0%+16.3%
TTM8.5%-11.5%+20.0%
YOY3.2%-10.8%+14.0%
5Y2.8%-14.2%+17.0%
10Y-13.6%-15.2%+1.6%

1.2. Operating Efficiency of Genovis AB (publ.).

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Genovis is operating .

  • Measures how much profit Genovis makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Genovis to the Biotechnology industry mean.
  • An Operating Margin of 18.6% means the company generated kr0.19  for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Genovis AB (publ.):

  • The MRQ is 18.6%. The company is operating efficient. +1
  • The TTM is 26.5%. The company is operating very efficient. +2
Trends
Current periodCompared to+/- 
MRQ18.6%TTM26.5%-7.8%
TTM26.5%YOY9.6%+16.9%
TTM26.5%5Y6.6%+19.8%
5Y6.6%10Y-277.1%+283.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ18.6%-207.3%+225.9%
TTM26.5%-271.0%+297.5%
YOY9.6%-325.9%+335.5%
5Y6.6%-454.0%+460.6%
10Y-277.1%-537.1%+260.0%
1.2.2. Operating Ratio

Measures how efficient Genovis is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.81 means that the operating costs are kr0.81 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Genovis AB (publ.):

  • The MRQ is 0.815. The company is less efficient in keeping operating costs low.
  • The TTM is 0.756. The company is efficient in keeping operating costs low. +1
Trends
Current periodCompared to+/- 
MRQ0.815TTM0.756+0.059
TTM0.756YOY0.889-0.133
TTM0.7565Y0.900-0.144
5Y0.90010Y8.472-7.571
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8152.871-2.056
TTM0.7563.504-2.748
YOY0.8893.604-2.715
5Y0.9005.132-4.232
10Y8.4726.371+2.101

1.3. Liquidity of Genovis AB (publ.).

1.3. Liquidity
1.3.1. Current Ratio

Measures if Genovis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 7.96 means the company has kr7.96 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Genovis AB (publ.):

  • The MRQ is 7.964. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.428. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.964TTM7.428+0.537
TTM7.428YOY5.479+1.948
TTM7.4285Y4.914+2.514
5Y4.91410Y3.788+1.126
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.9645.117+2.847
TTM7.4285.755+1.673
YOY5.4795.854-0.375
5Y4.9146.511-1.597
10Y3.7886.222-2.434
1.3.2. Quick Ratio

Measures if Genovis is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Genovis to the Biotechnology industry mean.
  • A Quick Ratio of 5.69 means the company can pay off kr5.69 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Genovis AB (publ.):

  • The MRQ is 5.688. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 5.474. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ5.688TTM5.474+0.213
TTM5.474YOY3.570+1.904
TTM5.4745Y3.127+2.347
5Y3.12710Y2.492+0.635
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.6884.284+1.404
TTM5.4744.664+0.810
YOY3.5704.787-1.217
5Y3.1275.218-2.091
10Y2.4925.182-2.690

1.4. Solvency of Genovis AB (publ.).

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Genovis assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Genovis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.16 means that Genovis assets are financed with 15.6% credit (debt) and the remaining percentage (100% - 15.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Genovis AB (publ.):

  • The MRQ is 0.156. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.158. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.156TTM0.158-0.002
TTM0.158YOY0.166-0.008
TTM0.1585Y0.244-0.086
5Y0.24410Y0.264-0.020
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1560.278-0.122
TTM0.1580.277-0.119
YOY0.1660.306-0.140
5Y0.2440.367-0.123
10Y0.2640.403-0.139
1.4.2. Debt to Equity Ratio

Measures if Genovis is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Genovis to the Biotechnology industry mean.
  • A Debt to Equity ratio of 18.5% means that company has kr0.18 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Genovis AB (publ.):

  • The MRQ is 0.185. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.188. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.185TTM0.188-0.004
TTM0.188YOY0.200-0.011
TTM0.1885Y0.348-0.160
5Y0.34810Y0.426-0.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1850.315-0.130
TTM0.1880.317-0.129
YOY0.2000.319-0.119
5Y0.3480.403-0.055
10Y0.4260.462-0.036

2. Market Valuation of Genovis AB (publ.)

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every kr1 in earnings Genovis generates.

  • Above 15 is considered overpriced but always compare Genovis to the Biotechnology industry mean.
  • A PE ratio of 384.79 means the investor is paying kr384.79 for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Genovis AB (publ.):

  • The EOD is 486.864. Seems overpriced? -1
  • The MRQ is 384.789. Seems overpriced? -1
  • The TTM is 1,270.092. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD486.864MRQ384.789+102.075
MRQ384.789TTM1,270.092-885.303
TTM1,270.092YOY2,651.222-1,381.131
TTM1,270.0925Y791.947+478.145
5Y791.94710Y365.652+426.295
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD486.864-8.986+495.850
MRQ384.789-9.792+394.581
TTM1,270.092-16.243+1,286.335
YOY2,651.222-20.876+2,672.098
5Y791.947-16.665+808.612
10Y365.652-14.732+380.384
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Genovis.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Genovis AB (publ.):

  • The MRQ is 436.135. Seems overpriced? -1
  • The TTM is 15.288. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ436.135TTM15.288+420.847
TTM15.288YOY-2,594.599+2,609.887
TTM15.2885Y-632.332+647.620
5Y-632.33210Y-370.851-261.482
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ436.135-0.032+436.167
TTM15.2880.004+15.284
YOY-2,594.5990.016-2,594.615
5Y-632.3320.006-632.338
10Y-370.8510.003-370.854

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Genovis is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 16.54 means the investor is paying kr16.54 for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Genovis AB (publ.):

  • The EOD is 20.926. Seems overpriced? -1
  • The MRQ is 16.539. Seems overpriced? -1
  • The TTM is 27.067. Seems overpriced? -1
Trends
Current periodCompared to+/- 
EOD20.926MRQ16.539+4.387
MRQ16.539TTM27.067-10.528
TTM27.067YOY30.986-3.919
TTM27.0675Y27.125-0.059
5Y27.12510Y19.814+7.311
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD20.9261.835+19.091
MRQ16.5392.006+14.533
TTM27.0672.774+24.293
YOY30.9863.453+27.533
5Y27.1252.713+24.412
10Y19.8142.402+17.412
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Genovis AB (publ.) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.0750.160-53%0.038+96%0.087-13%0.042+77%
Book Value Growth--0.9070.911-1%0.906+0%0.9100%0.901+1%
Book Value Per Share--2.0291.916+6%1.362+49%1.025+98%0.646+214%
Book Value Per Share Growth--0.0370.087-58%0.028+30%0.076-51%-0.016+144%
Current Ratio--7.9647.428+7%5.479+45%4.914+62%3.788+110%
Debt To Asset Ratio--0.1560.158-1%0.166-6%0.244-36%0.264-41%
Debt To Equity Ratio--0.1850.188-2%0.200-7%0.348-47%0.426-57%
Dividend Per Share----0%-0%-0%-0%
Eps--0.0870.156-44%0.043+102%0.043+102%-0.012+114%
Eps Growth--0.882-4.072+562%-2.450+378%-1.444+264%-0.534+160%
Gross Profit Margin--1.0001.0000%1.0000%1.100-9%1.050-5%
Net Profit Margin--0.2120.296-28%0.150+41%0.081+161%-2.936+1487%
Operating Margin--0.1860.265-30%0.096+94%0.066+181%-2.771+1588%
Operating Ratio--0.8150.756+8%0.889-8%0.900-9%8.472-90%
Pb Ratio20.926+21%16.53927.067-39%30.986-47%27.125-39%19.814-17%
Pe Ratio486.864+21%384.7891270.092-70%2651.222-85%791.947-51%365.652+5%
Peg Ratio--436.13515.288+2753%-2594.599+695%-632.332+245%-370.851+185%
Price Per Share42.450+21%33.55050.875-34%42.325-21%28.284+19%15.648+114%
Price To Total Gains Ratio565.992+21%447.3271097.445-59%2079.580-78%850.517-47%390.626+15%
Profit Growth--98.85850.802+95%66.532+49%22.112+347%-32.266+133%
Quick Ratio--5.6885.474+4%3.570+59%3.127+82%2.492+128%
Return On Assets--0.0360.070-48%0.027+37%0.023+58%-0.089+344%
Return On Equity--0.0430.085-49%0.032+33%0.028+54%-0.136+417%
Revenue Growth--0.9100.906+0%0.905+1%0.906+1%0.458+99%
Total Gains Per Share--0.0750.160-53%0.038+96%0.087-13%0.042+77%
Total Gains Per Share Growth--0.834-3.518+522%-0.658+179%-2.865+443%-2.915+449%
Usd Book Value--12881600.00012167695.132+6%8646561.037+49%6507926.168+98%4100744.479+214%
Usd Book Value Change Per Share--0.0070.016-53%0.004+96%0.008-13%0.004+77%
Usd Book Value Per Share--0.1970.186+6%0.132+49%0.099+98%0.063+214%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.0080.015-44%0.004+102%0.004+102%-0.001+114%
Usd Price Per Share4.118+21%3.2544.935-34%4.106-21%2.744+19%1.518+114%
Usd Profit--553676.000991931.336-44%274313.624+102%274480.658+102%-75388.373+114%
Usd Revenue--2615896.0003009801.918-13%1789909.984+46%1657049.307+58%989342.098+164%
Usd Total Gains Per Share--0.0070.016-53%0.004+96%0.008-13%0.004+77%
 EOD+2 -3MRQTTM+14 -18YOY+29 -35Y+23 -1010Y+29 -4

3.2. Fundamental Score

Let's check the fundamental score of Genovis AB (publ.) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15486.864
Price to Book Ratio (EOD)Between0-120.926
Net Profit Margin (MRQ)Greater than00.212
Operating Margin (MRQ)Greater than00.186
Quick Ratio (MRQ)Greater than15.688
Current Ratio (MRQ)Greater than17.964
Debt to Asset Ratio (MRQ)Less than10.156
Debt to Equity Ratio (MRQ)Less than10.185
Return on Equity (MRQ)Greater than0.150.043
Return on Assets (MRQ)Greater than0.050.036
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Genovis AB (publ.) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5052.247
Ma 20Greater thanMa 5043.420
Ma 50Greater thanMa 10039.366
Ma 100Greater thanMa 20043.075
OpenGreater thanClose42.650
Total3/5 (60.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in SEK. All numbers in thousands.

Summary
Total Assets157,317
Total Liabilities24,517
Total Stockholder Equity132,800
 As reported
Total Liabilities 24,517
Total Stockholder Equity+ 132,800
Total Assets = 157,317

Assets

Total Assets157,317
Total Current Assets113,406
Long-term Assets113,406
Total Current Assets
Cash And Cash Equivalents 80,987
Other Current Assets 32,419
Total Current Assets  (as reported)113,406
Total Current Assets  (calculated)113,406
+/-0
Long-term Assets
Property Plant Equipment 14,823
Intangible Assets 18,663
Other Assets 10,425
Long-term Assets  (as reported)43,911
Long-term Assets  (calculated)43,911
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities14,239
Long-term Liabilities10,278
Total Stockholder Equity132,800
Total Current Liabilities
Other Current Liabilities 14,239
Total Current Liabilities  (as reported)14,239
Total Current Liabilities  (calculated)14,239
+/-0
Long-term Liabilities
Other Liabilities 10,278
Long-term Liabilities  (as reported)10,278
Long-term Liabilities  (calculated)10,278
+/-0
Total Stockholder Equity
Common Stock132,800
Total Stockholder Equity (as reported)132,800
Total Stockholder Equity (calculated)132,800
+/-0
Other
Cash And Equivalents80,987
Cash and Short Term Investments 80,987
Common Stock Shares Outstanding 65,466
Liabilities and Stockholders Equity 157,317
Net Debt -80,987
Net Tangible Assets 114,137
Net Working Capital 99,167



Balance Sheet

Currency in SEK. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-03-31
> Total Assets 
0
16,564
0
0
14,759
14,544
25,724
20,737
17,818
14,500
28,370
24,895
21,442
18,165
29,650
25,801
18,158
13,311
23,852
20,103
41,448
37,888
33,601
27,790
19,562
16,509
25,180
17,822
16,914
21,660
26,314
23,157
21,851
19,196
26,347
24,972
26,305
30,573
42,719
39,203
37,827
39,585
42,792
54,611
49,044
95,332
98,841
98,123
106,648
107,932
106,667
106,365
141,750
147,062
149,323
157,317
157,317149,323147,062141,750106,365106,667107,932106,64898,12398,84195,33249,04454,61142,79239,58537,82739,20342,71930,57326,30524,97226,34719,19621,85123,15726,31421,66016,91417,82225,18016,50919,56227,79033,60137,88841,44820,10323,85213,31118,15825,80129,65018,16521,44224,89528,37014,50017,81820,73725,72414,54414,7590016,5640
   > Total Current Assets 
0
2,925
0
0
1,911
2,012
13,493
8,746
5,499
2,211
16,249
12,912
9,715
6,286
17,673
13,968
10,067
4,834
15,006
11,380
32,040
27,488
22,883
17,093
10,103
6,772
15,190
11,563
10,818
15,657
20,004
16,836
15,612
12,396
19,394
18,144
17,523
14,773
25,603
25,343
27,148
28,934
31,195
41,586
34,637
80,990
68,541
69,295
72,076
73,189
73,047
72,868
108,852
108,231
109,701
113,406
113,406109,701108,231108,85272,86873,04773,18972,07669,29568,54180,99034,63741,58631,19528,93427,14825,34325,60314,77317,52318,14419,39412,39615,61216,83620,00415,65710,81811,56315,1906,77210,10317,09322,88327,48832,04011,38015,0064,83410,06713,96817,6736,2869,71512,91216,2492,2115,4998,74613,4932,0121,911002,9250
       Cash And Cash Equivalents 
0
1,911
0
0
416
1,037
11,863
7,125
4,074
1,008
14,161
11,035
7,563
3,959
14,772
10,918
6,684
1,543
10,851
4,470
480
5,080
4,329
7,003
689
1,724
9,240
6,145
2,052
3,332
10,011
6,599
4,281
1,805
8,194
6,490
4,918
1,672
10,293
10,236
9,581
11,025
8,921
15,303
14,992
61,641
46,554
46,231
44,118
45,929
41,730
45,210
81,315
78,119
77,369
80,987
80,98777,36978,11981,31545,21041,73045,92944,11846,23146,55461,64114,99215,3038,92111,0259,58110,23610,2931,6724,9186,4908,1941,8054,2816,59910,0113,3322,0526,1459,2401,7246897,0034,3295,0804804,47010,8511,5436,68410,91814,7723,9597,56311,03514,1611,0084,0747,12511,8631,037416001,9110
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,000
3,000
18,000
12,500
5,000
5,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000005,0005,00012,50018,0003,0003,0000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
8,701
0
0
0
8,329
0
0
0
10,220
0
0
0
7,686
0
0
0
13,191
0
0
0
13,034
0
0
0
00013,03400013,1910007,68600010,2200008,3290008,70100000000000000000000000000000000
       Other Current Assets 
0
507
0
0
775
292
857
970
880
763
724
1,246
1,755
2,018
2,901
3,050
2,978
3,291
4,155
3,910
28,075
4,408
6,054
5,090
3,549
5,048
5,950
5,418
7,805
12,325
9,993
10,237
9,827
10,591
11,200
11,654
9,436
13,101
15,310
15,107
11,827
17,909
22,274
26,283
10,679
19,349
21,987
23,064
15,073
27,260
31,317
27,658
15,118
30,112
32,332
32,419
32,41932,33230,11215,11827,65831,31727,26015,07323,06421,98719,34910,67926,28322,27417,90911,82715,10715,31013,1019,43611,65411,20010,5919,82710,2379,99312,3257,8055,4185,9505,0483,5495,0906,0544,40828,0753,9104,1553,2912,9783,0502,9012,0181,7551,246724763880970857292775005070
   > Long-term Assets 
0
13,639
0
0
12,849
12,532
12,231
11,991
12,319
12,289
12,121
11,983
11,726
11,879
11,977
11,833
8,091
8,477
8,846
8,723
9,408
10,400
10,718
10,697
9,459
9,737
9,990
6,259
6,096
6,003
6,310
6,321
6,239
6,800
6,953
6,828
8,782
15,800
17,116
13,860
10,679
10,651
11,597
13,025
14,406
14,342
30,300
28,828
34,572
34,743
33,620
33,497
32,898
38,831
39,622
43,911
43,91139,62238,83132,89833,49733,62034,74334,57228,82830,30014,34214,40613,02511,59710,65110,67913,86017,11615,8008,7826,8286,9536,8006,2396,3216,3106,0036,0966,2599,9909,7379,45910,69710,71810,4009,4088,7238,8468,4778,09111,83311,97711,87911,72611,98312,12112,28912,31911,99112,23112,53212,8490013,6390
       Property Plant Equipment 
0
1,516
0
0
1,948
1,776
1,619
1,523
1,520
1,434
1,357
1,344
1,390
1,341
1,417
1,372
1,290
1,560
1,614
1,517
1,810
2,477
2,312
2,152
2,307
2,130
2,036
1,854
1,756
1,589
1,414
1,245
1,084
1,356
1,189
1,029
3,022
10,585
12,215
9,264
6,350
6,279
7,268
8,777
9,470
9,176
10,181
9,613
12,497
12,208
11,340
10,713
9,604
13,055
12,267
14,823
14,82312,26713,0559,60410,71311,34012,20812,4979,61310,1819,1769,4708,7777,2686,2796,3509,26412,21510,5853,0221,0291,1891,3561,0841,2451,4141,5891,7561,8542,0362,1302,3072,1522,3122,4771,8101,5171,6141,5601,2901,3721,4171,3411,3901,3441,3571,4341,5201,5231,6191,7761,948001,5160
       Goodwill 
0
0
0
0
0
0
0
0
0
0
4,107
4,106
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,729
0
0
0
4,118
0
0
0
0004,1180003,7290000000000000000000000000000000000004,1064,1070000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,718
1,718
0
1,718
0
1,718
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000001,71801,71801,7181,7180000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
3,766
3,632
0
7,373
0
0
3,426
0
0
0
4,162
4,487
4,970
5,109
5,434
5,889
6,236
2,687
2,622
2,696
3,178
3,358
3,438
3,726
4,046
4,081
4,042
3,497
3,183
2,878
2,611
2,654
2,611
2,530
3,218
3,448
18,321
17,420
12,103
16,315
16,236
16,384
12,357
16,639
17,774
18,663
18,66317,77416,63912,35716,38416,23616,31512,10317,42018,3213,4483,2182,5302,6112,6542,6112,8783,1833,4974,0424,0814,0463,7263,4383,3583,1782,6962,6222,6876,2365,8895,4345,1094,9704,4874,1620003,426007,37303,6323,7660000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
1,718
3,626
1,795
6,243
6,220
6,044
6,400
6,818
9,137
9,581
10,425
10,4259,5819,1376,8186,4006,0446,2206,2431,7953,6261,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,7181,71800000000000000000000000000000000
> Total Liabilities 
0
4,435
0
0
3,902
6,093
4,327
2,204
2,586
2,876
2,972
2,505
3,431
4,340
4,465
3,837
4,525
3,741
4,810
3,801
8,363
5,234
5,611
5,346
4,979
6,932
6,720
5,897
8,092
16,292
7,257
5,228
6,306
6,523
5,262
5,528
8,119
13,781
18,225
14,417
11,756
11,923
13,750
18,096
13,423
11,947
18,690
17,308
19,482
19,161
16,862
15,547
27,756
19,985
21,433
24,517
24,51721,43319,98527,75615,54716,86219,16119,48217,30818,69011,94713,42318,09613,75011,92311,75614,41718,22513,7818,1195,5285,2626,5236,3065,2287,25716,2928,0925,8976,7206,9324,9795,3465,6115,2348,3633,8014,8103,7414,5253,8374,4654,3403,4312,5052,9722,8762,5862,2044,3276,0933,902004,4350
   > Total Current Liabilities 
0
2,890
0
0
2,967
5,159
3,811
1,873
2,281
2,571
2,667
2,260
3,367
4,335
4,460
3,832
4,525
3,741
4,810
3,801
8,363
5,234
5,611
5,346
4,799
6,752
6,540
5,717
7,958
16,157
7,122
5,093
6,306
6,523
5,262
5,528
6,363
6,404
8,531
6,960
8,815
8,983
10,810
13,415
11,289
9,965
12,333
11,735
13,744
14,103
13,196
12,251
24,245
12,099
13,200
14,239
14,23913,20012,09924,24512,25113,19614,10313,74411,73512,3339,96511,28913,41510,8108,9838,8156,9608,5316,4046,3635,5285,2626,5236,3065,0937,12216,1577,9585,7176,5406,7524,7995,3465,6115,2348,3633,8014,8103,7414,5253,8324,4604,3353,3672,2602,6672,5712,2811,8733,8115,1592,967002,8900
       Short-term Debt 
0
0
0
0
480
0
0
0
120
0
0
0
180
0
0
0
0
0
0
0
0
0
0
0
46
0
0
0
46
0
0
0
135
0
0
0
352
7,377
9,694
626
2,231
0
0
0
2,547
0
0
0
3,344
0
0
0
1,708
0
0
0
0001,7080003,3440002,5470002,2316269,6947,3773520001350004600046000000000001800001200004800000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
135
0
0
0
352
7,377
9,694
626
2,231
0
0
0
2,547
0
0
0
0
0
0
0
0
0
0
0
000000000002,5470002,2316269,6947,37735200013500000000000000000000000000000000
       Accounts payable 
0
0
0
0
747
0
0
0
563
0
0
0
648
0
0
0
1,224
0
0
0
3,557
0
0
0
986
0
0
0
945
0
0
0
1,552
0
0
0
1,332
0
0
0
1,308
0
0
0
1,662
0
0
0
1,466
0
0
0
2,537
0
0
0
0002,5370001,4660001,6620001,3080001,3320001,5520009450009860003,5570001,2240006480005630007470000
       Other Current Liabilities 
0
2,890
0
0
1,740
5,159
3,811
1,873
1,598
2,571
2,667
2,260
2,539
4,335
4,460
3,832
3,301
3,741
4,810
3,801
4,807
5,234
5,611
5,346
3,767
6,752
6,540
5,717
6,967
16,157
7,122
5,093
4,620
6,523
5,262
5,528
4,679
6,404
8,531
6,960
5,277
8,983
10,810
13,415
7,080
9,965
12,333
11,735
8,934
14,103
13,196
12,251
20,000
12,099
13,200
14,239
14,23913,20012,09920,00012,25113,19614,1038,93411,73512,3339,9657,08013,41510,8108,9835,2776,9608,5316,4044,6795,5285,2626,5234,6205,0937,12216,1576,9675,7176,5406,7523,7675,3465,6115,2344,8073,8014,8103,7413,3013,8324,4604,3352,5392,2602,6672,5711,5981,8733,8115,1591,740002,8900
   > Long-term Liabilities 
0
1,545
0
0
935
934
516
331
305
305
305
245
65
5
5
5
0
0
0
0
0
0
0
0
180
180
180
180
135
135
135
135
0
0
0
0
1,755
7,377
9,694
7,457
2,940
2,940
2,940
4,681
2,134
1,982
6,357
5,573
5,739
5,058
3,666
3,296
3,511
7,886
8,233
10,278
10,2788,2337,8863,5113,2963,6665,0585,7395,5736,3571,9822,1344,6812,9402,9402,9407,4579,6947,3771,75500001351351351351801801801800000000055565245305305305331516934935001,5450
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,123
0
0
0
0001,1230000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,377
9,694
0
2,940
0
0
0
0
1,982
4,789
2,729
2,421
2,923
2,381
2,391
2,387
7,886
2,536
10,278
10,2782,5367,8862,3872,3912,3812,9232,4212,7294,7891,98200002,94009,6947,3770000000000000000000000000000000000000
> Total Stockholder Equity
0
12,129
0
0
10,858
8,451
21,397
18,533
15,232
11,624
25,398
22,390
18,010
13,825
25,185
21,964
13,633
9,570
19,042
16,302
33,085
32,654
27,990
22,444
14,583
9,577
18,460
11,925
8,822
5,368
19,057
17,929
15,545
12,673
21,085
19,444
18,187
16,792
24,494
24,786
26,071
27,662
29,042
36,515
35,621
83,385
80,151
80,815
87,165
88,771
89,805
90,818
113,994
127,077
127,890
132,800
132,800127,890127,077113,99490,81889,80588,77187,16580,81580,15183,38535,62136,51529,04227,66226,07124,78624,49416,79218,18719,44421,08512,67315,54517,92919,0575,3688,82211,92518,4609,57714,58322,44427,99032,65433,08516,30219,0429,57013,63321,96425,18513,82518,01022,39025,39811,62415,23218,53321,3978,45110,8580012,1290
   Common Stock
0
0
0
0
9,836
0
0
0
16,449
0
0
0
27,695
0
0
0
4,734
0
0
0
6,312
0
0
0
8,738
0
0
0
9,216
0
0
0
13,824
12,673
21,085
19,444
15,074
16,792
24,494
24,786
15,775
27,662
29,042
36,515
15,775
83,385
80,151
80,815
16,366
88,771
89,805
90,818
16,366
127,077
127,890
132,800
132,800127,890127,07716,36690,81889,80588,77116,36680,81580,15183,38515,77536,51529,04227,66215,77524,78624,49416,79215,07419,44421,08512,67313,8240009,2160008,7380006,3120004,73400027,69500016,4490009,8360000
   Retained Earnings Total Equity00000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-175
0
0
0
-24
0
0
0
-27
83,385
80,151
80,815
-4,500
88,771
89,805
90,818
213,206
127,077
127,890
132,800
132,800127,890127,077213,20690,81889,80588,771-4,50080,81580,15183,385-27000-24000-175000000000000000000000000000000000000



Balance Sheet

Currency in SEK. All numbers in thousands.




Cash Flow

Currency in SEK. All numbers in thousands.




Income Statement

Currency in SEK. All numbers in thousands.